Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lachgar

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC)A Lachgar, G Jaureguiberry, H Le Buenac, et al.
Cell Death and Differentiation|January 1, 1995
Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis?J F Zagury, V Chams, A Lachgar, et al.
Journal of Virology|January 9, 1999
Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteinsA Lachgar, N Sojic, S Arbault, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor mediumJ C Mazière, J C Landureau, P Giral, et al.
Blood|November 15, 1994
Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twinF Bex, P Hermans, S Sprecher, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunityO Picard, A Achour, J Bernard, et al.
Computer Applications in the Biosciences : CABIOS|June 1, 1995
Automat and BLAST: comparison of two protein sequence similarity search programsH Cantalloube, G Labesse, J Chomilier, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 1993
Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesisJ F Zagury, J Bernard, A Achour, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Removal of gp160 induced bio-hazards for a safe AIDS vaccine candidateO Picard, J Bernard, A Lachgar, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC)A Lachgar, G Jaureguiberry, H Le Buenac, et al.
Cell Death and Differentiation|January 1, 1995
Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis?J F Zagury, V Chams, A Lachgar, et al.
Journal of Virology|January 9, 1999
Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteinsA Lachgar, N Sojic, S Arbault, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 28, 1999
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoidH Le Buanec, A Lachgar, B Bizzini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor mediumJ C Mazière, J C Landureau, P Giral, et al.
Blood|November 15, 1994
Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twinF Bex, P Hermans, S Sprecher, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1992
A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunityO Picard, A Achour, J Bernard, et al.
Computer Applications in the Biosciences : CABIOS|June 1, 1995
Automat and BLAST: comparison of two protein sequence similarity search programsH Cantalloube, G Labesse, J Chomilier, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 1993
Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesisJ F Zagury, J Bernard, A Achour, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Removal of gp160 induced bio-hazards for a safe AIDS vaccine candidateO Picard, J Bernard, A Lachgar, et al.
Pageof 4